Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease , J Clin Oncol.: 2026

Metzger O, Mandrekar S, Goel S, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzàlez Farré X, Francis PA, Lynce F, Lanzillotti J, DuFrane C, Wall A, Strand C, Krop I, Vaz-Luis I, Tripathy D, Loi S, Prat A, Goetz M, Escrivá-de-Romaní S, Porter D, Spoenlein J, Stover DG, Sardesai S, Heudel P, Koehler M, Huang Bartlett C, Holynskyj A, Gopalakrishna P, Gauthier E, Delaloge S, Miller K, Winer EP, Gianni L, Partridge AH, DeMichele A, Carey LA. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer , N Engl J Med: 2026

Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. , Nat Commun: 2025

Chislock EM, Pan TC, Pant D, Chen Y, Woodfield G, Graves J, Lawrence-Paul MR, Belka GK, Wang J, Bayne L, Blanchard T, Smith M, Ji X, Shih NNC, Soucier-Ernst D, Goodman N, Nivar I, Goodspeed B, DeLuca S, Ndicu J, Clark C, Langer M, William Stavropoulos S, DeMuth W, Morschauser A, Murphy W, Nayak A, Feldman M, Clark A, Yu L, Judge K, Bornheimer S, Pletcher CH Jr, Moore JS, DeMichele A, Chodosh LA. DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer , NPJ Breast Cancer : 2025

Gerratana L, Reduzzi C, Ren Y, Jeselsohn R, Mahtani RL, Ma CX, DeMichele A, Meisel JL, Miller K, Abdou Y, Riley EC, Qamar R, Sharma P, Reid SA, Ko N, Liu Y, Gauthier E, Burstein HJ, DeMeo M, Tolaney SM, Regan MM, Cristofanilli M, Mayer EL. Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study. , Clin Cancer Res: 2025

Thomas A, Rhoads A, Mayer EL, O'Reilly S, Harbeck N, Curigliano G, Zhou Y, Adam V, Chan N, Conway KM, Ignatiadis M, Kalinsky K, DeMichele A, Romitti PA. Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021. , NPJ Breast Cancer: 2025

Hennessy, M. A., Gatsonis, C., Jacene, H., Connolly, R. M., Burnette, B. L., Stringer-Reasor, E. M., Romanoff, J., Taurone, A., O'Sullivan, C. C., Le-Petross, H. T., Stearns, V., Fowler, A. M., Tang, S., Sepulveda, K. A., DeMichele, A. M., Mankoff, D. A., Wolff, A. C. EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial) , Future Oncology : 2025

DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nature Medicine: 2025

Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial , Ann Surg Oncol.: 2025

Mukhtar, R. A., Dimitroff, K., Yau, C., Chien, A. J., Connolly, E. P., Howard-McNatt, M., Rao, R., Ladores, V., Golshan, M., Sauder, C. A., Ahmed, K., Lancaster, R., Fox, J., Gutnik, L., Lee, M. C., Tchou, J., Prionas, N., Arciero, C. A., Reyna, C., Kuerer, H., Switalla, K., Taunk, N., Tuttle, T. M., Moran, M. S., Postlewait, L. M., Perlmutter, J., DeMichele, A., Yee, D., Hylton, N., Symmans, W. F., Rugo, H. S., Shatsky, R., Isaacs, C., Esserman, L. J., Van't Veer, L., Boughey, J. C. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial , Annals of surgical oncology: 2025